The onset of skeletal metastases is typical of advanced-stage prostate cancer and requires a
multidisciplinary approach to alleviate bone pain and try to delay disease progression. The …

Objective This open-label, non-randomized, phase I study examined the pharmacokinetics
(PK) and radiation dosimetry of a single dose of radium-223 in Japanese patients with …

Results A total of 145 patients were included; the median age was 73.97 years, and a
Gleason score of more than or equal to 7 in 61 (48%) patients; 73 (81%) had previously …

Aim of Study: There is limited information regarding the α-emitter radiopharmaceuticals dose
calculation used in the setting of men with prostate cancer (PCa). The present study …

Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant
prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone …

Background Radium-223 dichloride (Ra-223 Xofigo) has recently been approved as an
addition to the host of available therapies in the USA as a treatment option for metastatic …

Prostate cancer is the most frequent cancer amongst men. Until recently, only two
therapeutic options, initial androgen-deprivation therapy in patients without castration …

Painful bone metastases are common in prostate cancer, with current treatments including
non-steroidal analgesics and opiates, surgery, external beam radiotherapy and bone …

Metastatic skeletal disease is the cause of considerable morbidity in patients with advanced
Castration-Resistant Prostate Cancer (CRPC). It is considered that bone metastasis is the …

A prosztatadaganat kezelésében az utóbbi évtized jelentős fejlődést eredményezett,
javultak a daganat felismerésének lehetőségei azáltal, hogy pontosabb diagnosztikai …